Get all your news in one place.
100's of premium titles.
One app.
Start reading
Birmingham Post
Birmingham Post
Business
Jon Robinson

Shares in drug maker more then double after agreeing $160m deal

Shares in a clinical stage drug development have more than doubled in value after it revealed a $160.5m deal.

Evgen Pharma, which is listed on AIM and has bases in Liverpool and Wimslow, has licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla SA.

The Swiss company specialises in the identification of specific phenotypes of autism spectrum disorder (ASD).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.